The company highlights the risk of patent invalidation, which could shorten market exclusivity for its products and allow the FDA to approve generic versions sooner.
Filing excerpt
If we are unsuccessful in these proceedings some or all of our claims in the patents may be narrowed or invalidated and the patent protection for our products and drug candidates in the United States could be substantially shortened.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10qcompetitorNamedGet every 10-Q signal for Incyte and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/86a9ba25-afe1-4780-836b-d35d610a44f9 returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.
{
"signal_id": "86a9ba25-afe1-4780-836b-d35d610a44f9",
"signal_type": "sec-10q",
"signal_subtype": "competitorNamed",
"detected_at": "2026-05-05T08:48:21.69+00:00",
"company": {
"name": "Incyte",
"domain": "incyte.com"
},
"data": {
"detail": "The company highlights the risk of patent invalidation, which could shorten market exclusivity for its products and allow the FDA to approve generic versions sooner. This competitive pressure creates an urgent need for solutions that can accelerate new drug pipelines, manage IP litigation, and maximize revenue from existing patents.",
"metrics": {
"timeframe": "current_year"
},
"summary": "Incyte faces patent invalidation risk, potentially opening doors to generic competition.",
"excerpts": "If we are unsuccessful in these proceedings some or all of our claims in the patents may be narrowed or invalidated and the patent protection for our products and drug candidates in the United States could be substantially shortened.",
"relevance": 0.7,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000026/incy-20260331.htm",
"filing_date": "2026-04-28",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "03/31",
"sales_relevance": "Competitive intelligence",
"signal_category": "market",
"regions_mentioned": [
"United States"
]
}
}
curl https://signals.autobound.ai/v1/signals/86a9ba25-afe1-4780-836b-d35d610a44f9 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.